Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.

ABSTRACT:

Background

There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis.

Objectives

Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS).

Methods

We retrospectively reviewed ambulatory function as measured by timed 25-foot walk (T25FW) in clinical trial subjects with an Expanded Disability Status Scale score ≥3.5, including RRMS subjects from the phase 3 AFFIRM and SENTINEL trials, relapsing SPMS subjects from the phase 2 MS231 study, and nonrelapsing SPMS subjects from the phase 1b DELIVER study. For comparison, SPMS subjects from the intramuscular interferon beta-1a (IM IF

SUBMITTER: Cadavid D 

PROVIDER: S-EPMC3537666 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature